Literature DB >> 24259049

Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain.

Eloise Hudry1, Jonathan Dashkoff, Alysson D Roe, Shuko Takeda, Robert M Koffie, Tadafumi Hashimoto, Maria Scheel, Tara Spires-Jones, Michal Arbel-Ornath, Rebecca Betensky, Beverly L Davidson, Bradley T Hyman.   

Abstract

Inheritance of the ε4 allele of apolipoprotein E (APOE) is the strongest genetic risk factor associated with the sporadic form of Alzheimer's disease (AD), whereas the rare APOE ε2 allele has the opposite effect. However, the mechanisms whereby APOE confers risk and protection remain uncertain. We used a gene transfer approach to bathe the cortex of amyloid plaque-bearing transgenic mice with virally expressed human APOE. We monitored amyloid-β (Aβ) with multiphoton imaging, in vivo microdialysis, and postmortem array tomography to study the kinetics of human APOE-mediated changes in Aβ-related neurotoxicity in a mouse model of AD. We observed that human APOE4 increased the concentrations of oligomeric Aβ within the interstitial fluid and exacerbated plaque deposition; the converse occurred after exposure to human APOE2. Peri-plaque synapse loss and dystrophic neurites were also worsened by APOE4 or attenuated by APOE2. Egress of Aβ from the central nervous system (CNS) into the plasma was diminished by APOE3 and APOE4 compared to APOE2, in accord with isoform-specific retention of Aβ in the CNS. Overall, our data show a differential effect of human APOE isoforms on amyloid deposition and clearance in transgenic mice and, more importantly, on Aβ-mediated synaptotoxicity. These results suggest that the APOE genetic risk is mediated by Aβ, and that therapeutic approaches aimed at decreasing APOE4, or increasing APOE2, may be beneficial in AD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24259049      PMCID: PMC4334150          DOI: 10.1126/scitranslmed.3007000

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  53 in total

Review 1.  An inherited variable poly-T repeat genotype in TOMM40 in Alzheimer disease.

Authors:  Allen D Roses
Journal:  Arch Neurol       Date:  2010-05

2.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

3.  Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques.

Authors:  Robert M Koffie; Melanie Meyer-Luehmann; Tadafumi Hashimoto; Kenneth W Adams; Matthew L Mielke; Monica Garcia-Alloza; Kristina D Micheva; Stephen J Smith; M Leo Kim; Virginia M Lee; Bradley T Hyman; Tara L Spires-Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-19       Impact factor: 11.205

4.  Novel microdialysis method to assess neuropeptides and large molecules in free-moving mouse.

Authors:  S Takeda; N Sato; K Ikimura; H Nishino; H Rakugi; R Morishita
Journal:  Neuroscience       Date:  2011-04-20       Impact factor: 3.590

5.  Stimulation of the retinoid X receptor facilitates beta-amyloid clearance across the blood-brain barrier.

Authors:  Corbin Bachmeier; David Beaulieu-Abdelahad; Fiona Crawford; Michael Mullan; Daniel Paris
Journal:  J Mol Neurosci       Date:  2012-08-14       Impact factor: 3.444

6.  Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β.

Authors:  Robert M Koffie; Tadafumi Hashimoto; Hwan-Ching Tai; Kevin R Kay; Alberto Serrano-Pozo; Daniel Joyner; Steven Hou; Katherine J Kopeikina; Matthew P Frosch; Virginia M Lee; David M Holtzman; Bradley T Hyman; Tara L Spires-Jones
Journal:  Brain       Date:  2012-05-26       Impact factor: 13.501

Review 7.  Structural correlates of cognition in dementia: quantification and assessment of synapse change.

Authors:  S T DeKosky; S W Scheff; S D Styren
Journal:  Neurodegeneration       Date:  1996-12

8.  Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice.

Authors:  K Hsiao; P Chapman; S Nilsen; C Eckman; Y Harigaya; S Younkin; F Yang; G Cole
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

9.  Frequency of the apolipoprotein E epsilon 2 allele is diminished in sporadic Alzheimer disease.

Authors:  H L West; G W Rebeck; B T Hyman
Journal:  Neurosci Lett       Date:  1994-07-04       Impact factor: 3.046

10.  In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life.

Authors:  John R Cirrito; Patrick C May; Mark A O'Dell; Jennie W Taylor; Maia Parsadanian; Jeffrey W Cramer; James E Audia; Jeffrey S Nissen; Kelly R Bales; Steven M Paul; Ronald B DeMattos; David M Holtzman
Journal:  J Neurosci       Date:  2003-10-01       Impact factor: 6.167

View more
  67 in total

Review 1.  Amyloid beta: structure, biology and structure-based therapeutic development.

Authors:  Guo-Fang Chen; Ting-Hai Xu; Yan Yan; Yu-Ren Zhou; Yi Jiang; Karsten Melcher; H Eric Xu
Journal:  Acta Pharmacol Sin       Date:  2017-07-17       Impact factor: 6.150

2.  A flow cytometry-based in vitro assay reveals that formation of apolipoprotein E (ApoE)-amyloid beta complexes depends on ApoE isoform and cell type.

Authors:  Eleanna Kara; Jordan D Marks; Allyson D Roe; Caitlin Commins; Zhanyun Fan; Maria Calvo-Rodriguez; Susanne Wegmann; Eloise Hudry; Bradley T Hyman
Journal:  J Biol Chem       Date:  2018-06-27       Impact factor: 5.157

3.  AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease.

Authors:  Jonathan B Rosenberg; Michael G Kaplitt; Bishnu P De; Alvin Chen; Thomas Flagiello; Christiana Salami; Eduard Pey; Lingzhi Zhao; Rodolfo J Ricart Arbona; Sebastien Monette; Jonathan P Dyke; Douglas J Ballon; Stephen M Kaminsky; Dolan Sondhi; Gregory A Petsko; Steven M Paul; Ronald G Crystal
Journal:  Hum Gene Ther Clin Dev       Date:  2018-03-13       Impact factor: 5.032

Review 4.  Viral vectors for therapy of neurologic diseases.

Authors:  Sourav R Choudhury; Eloise Hudry; Casey A Maguire; Miguel Sena-Esteves; Xandra O Breakefield; Paola Grandi
Journal:  Neuropharmacology       Date:  2016-02-21       Impact factor: 5.250

5.  Apolipoprotein E*4 (APOE*4) Genotype Is Associated with Altered Levels of Glutamate Signaling Proteins and Synaptic Coexpression Networks in the Prefrontal Cortex in Mild to Moderate Alzheimer Disease.

Authors:  Robert A Sweet; Matthew L MacDonald; Caitlin M Kirkwood; Ying Ding; Tadhg Schempf; Jackie Jones-Laughner; Julia Kofler; Milos D Ikonomovic; Oscar L Lopez; Megan E Garver; Nicholas F Fitz; Radosveta Koldamova; Nathan A Yates
Journal:  Mol Cell Proteomics       Date:  2016-04-21       Impact factor: 5.911

Review 6.  Three dimensions of the amyloid hypothesis: time, space and 'wingmen'.

Authors:  Erik S Musiek; David M Holtzman
Journal:  Nat Neurosci       Date:  2015-06       Impact factor: 24.884

Review 7.  Mitochondrial dysfunction in Alzheimer's disease: Role in pathogenesis and novel therapeutic opportunities.

Authors:  Judit M Perez Ortiz; Russell H Swerdlow
Journal:  Br J Pharmacol       Date:  2019-03-06       Impact factor: 8.739

8.  Anti-ApoE antibody given after plaque onset decreases Aβ accumulation and improves brain function in a mouse model of Aβ amyloidosis.

Authors:  Fan Liao; Yukiko Hori; Eloise Hudry; Adam Q Bauer; Hong Jiang; Thomas E Mahan; Katheryn B Lefton; Tony J Zhang; Joshua T Dearborn; Jungsu Kim; Joseph P Culver; Rebecca Betensky; David F Wozniak; Bradley T Hyman; David M Holtzman
Journal:  J Neurosci       Date:  2014-05-21       Impact factor: 6.167

Review 9.  Gene therapy for the nervous system: challenges and new strategies.

Authors:  Casey A Maguire; Servio H Ramirez; Steven F Merkel; Miguel Sena-Esteves; Xandra O Breakefield
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

10.  Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β-amyloidosis.

Authors:  Tien-Phat V Huynh; Fan Liao; Caroline M Francis; Grace O Robinson; Javier Remolina Serrano; Hong Jiang; Joseph Roh; Mary Beth Finn; Patrick M Sullivan; Thomas J Esparza; Floy R Stewart; Thomas E Mahan; Jason D Ulrich; Tracy Cole; David M Holtzman
Journal:  Neuron       Date:  2017-12-06       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.